Janssen Search
Search results
Michelle Kramer, M.D., M.P.H.
MICHELLE KRAMER, M.D., M.P.H. GLOBAL HEAD OF DEVELOPMENT Michelle Kramer, M.D., M.P.H. is the Global Head of Development for Neuroscience at Janssen Research & Development. With more than two decades of experience at Janssen and Johnson & Johnson, ...
Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023
Sep 05, 2023 United States Key analyses examine long-term safety and efficacy of medicines for treatment-resistant depression and schizophrenia Titusville, New Jersey, September 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson ...
Jochen Fleischmann
JOCHEN FLEISCHMANN VICE PRESIDENT GLOBAL THERAPEUTIC AREA MARKET ACCESS LEADER IMMUNOLOGY Jochen Fleischmann is the Vice President, Global Therapeutic Area Market Access Leader, Immunology, for the Janssen Pharmaceutical Companies of Johnson & Johnson ...
Johnson & Johnson pivotal study of seltorexant shows statistically significant and clinically meaningful improvement in depressive symptoms and sleep disturbance outcomes
May 29, 2024 Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP 2024 Approximately 60 ...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Jul 22, 2024 Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of ...
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024
May 30, 2024 NEW BRUNSWICK, N.J., May 30, 2024 – Johnson & Johnson (NYSE: JNJ) today announced William N. (Bill) Hait, M.D., Ph.D., will retire from his position as Executive Vice President, Chief External Innovation and Medical Officer, in September ...